Evidence map›Paper›PMID 25865225›Full record

SynthesisOncotarget2015

Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer.

Yi Shen, Dionyssios Katsaros, Lenora W M Loo, Brenda Y Hernandez, Clayton Chong, Emilie Marion Canuto, Nicoletta Biglia, Lingeng Lu, Harvey Risch, Wen-Ming Chu and 1 more

Open access · diamondAbstract readComparative StudyMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Yi ShenCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Dionyssios KatsarosDepartment of Surgical Sciences, Azienda Ospedaliero-Universitaria, Turin, Italy.
Lenora W M LooCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Brenda Y HernandezCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Clayton ChongCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Emilie Marion CanutoDepartment of Surgical Sciences, Azienda Ospedaliero-Universitaria, Turin, Italy.
Nicoletta BigliaDepartment of Surgical Sciences, University of Turin, Torino, Italy.
Lingeng LuDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
Harvey RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
Wen-Ming ChuCancer Biology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Herbert YuCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
University of Hawaiʻi at Mānoa · USCancer Center of Hawaii · USOspedale Sant'Anna · ITYale University · USUniversity of Hawaii Cancer CenterUniversity of Turin · IT

Funding

University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Xin Chen · 1996 to 2026
$56.2M
NCI NIH HHS P30 CA071789
6 · The paper itself

Abstract

LINC00472 is a novel long intergenic non-coding RNA. We evaluated LINC00472 expression in breast tumor samples using RT-qPCR, performed a meta-analysis of over 20 microarray datasets from the Gene Expression Omnibus (GEO) database, and investigated the effect of LINC00472 expression on cell proliferation and migration in breast cancer cells transfected with a LINC00472-expressing vector. Our qPCR results showed that high LINC00472 expression was associated with less aggressive breast tumors and more favorable disease outcomes. Patients with high expression of LINC00472 had significantly reduced risk of relapse and death compared to those with low expression. Patients with high LINC00472 expression also had better responses to adjuvant chemo- or hormonal therapy than did patients with low expression. Results of meta-analysis on multiple studies from the GEO database were in agreement with the findings of our study. High LINC00472 was also associated with favorable molecular subtypes, Luminal A or normal-like tumors. Cell culture experiments showed that up-regulation of LINC00472 expression could suppress breast cancer cell proliferation and migration. Collectively, our clinical and in vitro studies suggest that LINC00472 is a tumor suppressor in breast cancer. Evaluating this long non-coding RNA in breast tumors may have prognostic and predictive value in the clinical management of breast cancer.

Indexed as

Genes, Tumor SuppressorAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsCarcinomaCell DivisionCell Line, TumorCell MovementChemotherapy, AdjuvantDisease-Free SurvivalFemaleGene ExpressionGenetic VectorsHumansAntineoplastic Agents, HormonalLINC00472 RNA, humanRNARNA, Long NoncodingRNA, NeoplasmRNA, recombinantbreastLINC00472lincRNA

Identifiers

PMID25865225
PMCPMC4496168
OpenAlexW1759563280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.